MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tams, J. W.
Right arrow Articles by Fahrenkrug, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tams, J. W.
Right arrow Articles by Fahrenkrug, J.

Vol. 58, Issue 5, 1035-1041, November 2000

Creation of a Selective Antagonist and Agonist of the Rat VPAC1 Receptor Using a Combinatorial Approach with Vasoactive Intestinal Peptide 6-23 as Template

Jeppe Wegener Tams, Rikke Malene Jørgensen, Arne Holm, and Jan Fahrenkrug

Department of Clinical Biochemistry, Bispebjerg Hospital, Copenhagen, Denmark (J.W.T., J.F.); and Chemistry Department, The Royal Veterinary and Agricultural University, Copenhagen, Denmark (R.M.J., A.H.)

We have used combinatorial chemistry with amino acid mixtures (X) at positions 6 to 23 in vasoactive intestinal peptide (VIP) to optimize binding affinity and selectivity to the rat VPAC1 receptor. The most efficient amino acid replacement was a substitution of alanine at position 18 to diphenylalanine (Dip), increasing the displacement efficiency of 125I-VIP by 370-fold. The [Dip18]VIP(6-23) was subsequently used to find a second replacement, employing the same approach. Tyrosine at position 9 was selected and the resulting [Tyr9,Dip18]VIP(6-23) analog has a Ki value of 90 nM. This analog was unable to stimulate cAMP production at 10-6 M but was able to inhibit VIP-induced cAMP stimulation (Kb = 79 nM). The Ki values of [Tyr9,Dip18]VIP(6-23) using the rat VPAC2 and PAC1 receptors were 3,000 nM and >10,000 nM, respectively. Thus, [Tyr9,Dip18]VIP(6-23) is a selective VPAC1 receptor antagonist. The C-terminally extended form, [Tyr9,Dip18]VIP(6-28), displays improved antagonistic properties having a Ki and Kb values of 18 nM and 16 nM, respectively. On the contrary, the fully extended form, [Tyr9,Dip18]VIP(1-28), was a potent agonist with improved binding affinity (Ki = 0.11 nM) and ability to stimulate cAMP (EC50 = 0.23 nM) compared with VIP (Ki = 1.7 nM, EC50 = 1.12 nM). Furthermore, the specificity of this agonist to the VPAC1 receptor was high, the Ki values for the VPAC2 and PAC1 receptors were 53 nM and 3,100 nM, respectively. Seven other analogs with the [Tyr9,Dip18] replacement combined with previously published VIP modifications have been synthesized and described in this work.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics